Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 223,511,392
  • Shares Outstanding, K 2,044,000
  • Annual Sales, $ 46,660 M
  • Annual Income, $ 14,850 M
  • EBIT $ 11,380 M
  • EBITDA $ 19,763 M
  • 60-Month Beta 0.58
  • Price/Sales 4.88
  • Price/Cash Flow 9.89
  • Price/Book 5.17

Options Overview Details

View History
  • Implied Volatility 20.68% ( -0.24%)
  • Historical Volatility 17.24%
  • IV Percentile 81%
  • IV Rank 64.14%
  • IV High 25.21% on 04/19/24
  • IV Low 12.60% on 05/16/24
  • Put/Call Vol Ratio 1.46
  • Today's Volume 1,542
  • Volume Avg (30-Day) 1,644
  • Put/Call OI Ratio 1.49
  • Today's Open Interest 49,386
  • Open Int (30-Day) 48,493

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.85
  • Number of Estimates 4
  • High Estimate 1.95
  • Low Estimate 1.78
  • Prior Year 1.53
  • Growth Rate Est. (year over year) +20.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.93 +1.31%
on 10/31/24
117.36 -6.83%
on 10/18/24
-5.20 (-4.54%)
since 10/01/24
3-Month
107.93 +1.31%
on 10/31/24
120.92 -9.57%
on 08/30/24
-2.75 (-2.45%)
since 08/01/24
52-Week
92.35 +18.41%
on 04/18/24
120.92 -9.57%
on 08/30/24
+15.09 (+16.01%)
since 11/01/23

Most Recent Stories

More News
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...

BAYRY : 6.8000 (+0.44%)
NVS : 109.35 (+0.88%)
REGN : 843.60 (+0.64%)
SNY : 53.27 (+0.74%)
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript

NVS earnings call for the period ending September 30, 2024.

NVS : 109.35 (+0.88%)
3 Absurdly Cheap Stocks That Pay High Dividends

These stocks are trading at less than 15 times their expected future profits.

MRK : 101.88 (-0.43%)
NVS : 109.35 (+0.88%)
GILD : 89.51 (+0.78%)
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

For Immediate ReleaseChicago, IL – October 24, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 111.94 (-0.01%)
NVS : 109.35 (+0.88%)
REGN : 843.60 (+0.64%)
PFE : 28.09 (-0.74%)
BIIB : 173.79 (-0.12%)
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

For Immediate ReleaseChicago, IL – October 23, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 111.94 (-0.01%)
NVS : 109.35 (+0.88%)
REGN : 843.60 (+0.64%)
PFE : 28.09 (-0.74%)
BIIB : 173.79 (-0.12%)
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson reported strong third-quarter results, beating estimates for earnings and sales. J&J consequently...

NVO : 111.94 (-0.01%)
NVS : 109.35 (+0.88%)
REGN : 843.60 (+0.64%)
PFE : 28.09 (-0.74%)
BIIB : 173.79 (-0.12%)
Novartis Gets CHMP Recommendation for Kisqali in Broader Population

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali (ribociclib)...

BAYRY : 6.8000 (+0.44%)
LLY : 818.93 (-1.30%)
NVS : 109.35 (+0.88%)
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move

Novartis is taking a more calculated and strategic approach to its growth.

NVS : 109.35 (+0.88%)
Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU

Bayer BAYRY announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (“EMA”) for its pipeline candidate elinzanetant.The MAA is seeking approval...

BAYRY : 6.8000 (+0.44%)
LLY : 818.93 (-1.30%)
NVS : 109.35 (+0.88%)
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

/CNW/ -- With every October, breast cancer awareness surges thanks to very effective campaigns and new developments in breast cancer treatment. However, this...

ONCY : 1.1800 (+2.61%)
HOLX : 82.33 (+1.81%)
KZIA : 5.52 (+2.22%)
ATOS : 1.4200 (+2.90%)
NVS : 109.35 (+0.88%)
ONC.TO : 1.66 (+4.40%)
KZA.AX : 0.080 (+9.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 110.54
2nd Resistance Point 110.28
1st Resistance Point 109.82
Last Price 109.35
1st Support Level 109.09
2nd Support Level 108.83
3rd Support Level 108.37

See More

52-Week High 120.92
Fibonacci 61.8% 110.01
Last Price 109.35
Fibonacci 50% 106.63
Fibonacci 38.2% 103.26
52-Week Low 92.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar